ADCs	Antibody-Drug Conjugates
AIS	Adenocarcinoma In Situ
BFv	Bulumtatug Fuvedotin
CCRT	Concurrent Chemoradiotherapy (CCRT)
CIN	Cervical Intraepithelial Neoplasia
circRNA	Circular RNA
CRT	Chemoradiation
DAMPs	Damage-Associated Molecular Patterns
DCR	Disease Control Rate
DLT	Dose-limiting toxicities
E	Endostar
EMT	Epithelial–Mesenchymal Transition
FIGO	International Federation of Gynecology and Obstetrics (Fédération Internationale de Gynécologie et d’Obstétrique)
GI	Gastrointestinal
GU	Genitourinary
HIV	Human Immunodeficiency Virus
HPV	Human Papillomaviruses
HR	Hazard Ratio
hTERT	Human Telomerase Reverse Transcriptase
IFP	Interstitial Fluid Pressure
LACC	Locally Advanced Cervical Cancer
lncRNA	Long Non-Coding RNA
mAb	Monoclonal Antibody
MHC	Major Histocompatibility
miRNA	MicroRNA
ORR	Objective Response Rate
OS	Overall Survival
PFS	Progression-Free Survival
RCT	Randomized Controlled trial
SCC	Squamous Cell Carcinoma
TAMs	Tumor-Associated Macrophages
TF	Tissue Factor
TKI	Tyrosine Kinase Inhibitor
TPP1	Tripeptidyl Peptidase 1
TV	Tisotumab Vedotin
VEGF-A	Vascular Endothelial Growth Factor A
VEGFR	Vascular Endothelial Growth Factor Receptor
VLP	Virus-Like Particle
VN	Vascular Normalization